Greenwich LifeSciences, Inc.
GLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.38 | 0.16 | -0.02 |
| FCF Yield | -1.97% | -1.84% | -1.46% | -1.25% |
| EV / EBITDA | -31.60 | -29.21 | -37.46 | -17.86 |
| Quality | ||||
| ROIC | -191.06% | -281.07% | -250.12% | -319.02% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.64 | 0.55 | 0.56 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -19.62% | -21.73% | 0.96% | 28.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 0.77 | 0.84 | 0.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -110,510.03 | -82,428.84 | -58,681.20 |